{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:24:36Z","timestamp":1787261076113,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014489","name":"Johnson and Johnson Pharmaceutical Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.chest.2025.12.013","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:08:02Z","timestamp":1766246882000},"page":"1330-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"169","author":[{"given":"Maurice","family":"Beghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Nygaard","family":"Axelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian I.","family":"Borissoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sining","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Russu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Reme\u0148ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Hsu Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Moledina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2025.12.013_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"38","key":"10.1016\/j.chest.2025.12.013_bib2","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.chest.2025.12.013_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","article-title":"Pulmonary arterial hypertension: a comparison between children and adults","volume":"37","author":"Barst","year":"2011","journal-title":"Eur Respir J"},{"issue":"113","key":"10.1016\/j.chest.2025.12.013_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1183\/09059180.00003309","article-title":"Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease","volume":"18","author":"Gatzoulis","year":"2009","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.chest.2025.12.013_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01345-2024","article-title":"Embracing the challenges of neonatal and paediatric pulmonary hypertension","volume":"64","author":"Ivy","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.013_bib6","unstructured":"US Food and Drug Administration, E11A Pediatric Extrapolation. Final guidance document, US Food and Drug Administration website. Accessed January 28, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e11a-pediatric-extrapolation"},{"key":"10.1016\/j.chest.2025.12.013_bib7","unstructured":"European Medicines Agency. Extrapolation of efficacy and safety in paediatric medicine development - scientific guideline. European Medicines Agency website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/extrapolation-efficacy-safety-paediatric-medicine-development-scientific-guideline"},{"issue":"4","key":"10.1016\/j.chest.2025.12.013_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.013_bib9","unstructured":"US Food and Drug Administration. Highlights of prescribing information. US Food and Drug Administration website. Accessed January 28, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021290s044,209279s010lbl.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib10","unstructured":"US Food and Drug Administration. Highlights of prescribing information. US Food and Drug Administration website. Accessed January 28, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021845Orig1s028lbl.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib11","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/volibris-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib12","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tracleer-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib13","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opsumit-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib14","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revatio-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib15","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcirca-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib16","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adempas-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib17","unstructured":"EMA. Summary of product characteristics. EMA website. Accessed January 28, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/uptravi-epar-product-information_en.pdf"},{"key":"10.1016\/j.chest.2025.12.013_bib18","unstructured":"US Food and Drug Administration. Highlights of prescribing information. US Food and Drug Administration website. Accessed January 28, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207947s009lbl.pdf"},{"issue":"26","key":"10.1016\/j.chest.2025.12.013_bib19","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2025.12.013_bib20","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/psp4.13231","article-title":"Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension","volume":"13","author":"Axelsen","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.chest.2025.12.013_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bjs.1800670314","article-title":"Intussusception in infancy and childhood","volume":"67","author":"Hutchison","year":"1980","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.chest.2025.12.013_bib22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/bjs.1800790906","article-title":"Paediatric intussusception","volume":"79","author":"Stringer","year":"1992","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.chest.2025.12.013_bib23","first-page":"266","article-title":"Intussusception in babies under 4 months of age","volume":"136","author":"Newman","year":"1987","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.chest.2025.12.013_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0736-4679(91)90379-T","article-title":"Unusual cases of intussusception","volume":"9","author":"Pollack","year":"1991","journal-title":"J Emerg Med"},{"issue":"11","key":"10.1016\/j.chest.2025.12.013_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/PEC.0b013e31818c2a3e","article-title":"Intussusception","volume":"24","author":"Waseem","year":"2008","journal-title":"Pediatr Emerg Care"},{"issue":"9318","key":"10.1016\/j.chest.2025.12.013_bib27","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2025.12.013_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/pharmaceutics15020701","article-title":"Acceptability, swallowability, palatability, and safety of multiple film-coated mini-tablets in children aged \u22652-<7 years: results of an open-label randomised study","volume":"15","author":"M\u00fcnch","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.chest.2025.12.013_bib29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1253\/circj.CJ-16-1348","article-title":"Efficacy and safety of an orally administered selective prostacyclin receptor agonist, selexipag, in Japanese patients with pulmonary arterial hypertension","volume":"81","author":"Tanabe","year":"2017","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.chest.2025.12.013_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.013_bib31","doi-asserted-by":"crossref","unstructured":"NICE. Selexipag: side-effects. NICE website. Accessed January 28, 2026. https:\/\/bnf.nice.org.uk\/drugs\/selexipag\/","DOI":"10.55277\/rhj.hh77snvj"},{"key":"10.1016\/j.chest.2025.12.013_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.114221","article-title":"Safety and effectiveness of selexipag in pediatric pulmonary hypertension: a retrospective multicenter cohort study","volume":"275","author":"Frank","year":"2024","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.chest.2025.12.013_bib33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s00246-024-03513-w","article-title":"Selexipag dosing strategies for pediatric patients with pulmonary arterial hypertension","volume":"46","author":"Grossman","year":"2025","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2025.12.013_bib34","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.healun.2025.02.159","article-title":"10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension (PAH) from the GRIPHON study and its open-label extension (OLE)","volume":"44","author":"McLaughlin","year":"2025","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.chest.2025.12.013_bib35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.healun.2023.09.016","article-title":"Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)","volume":"43","author":"McLaughlin","year":"2024","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.chest.2025.12.013_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.202110-2428OC","article-title":"Twenty-year experience and outcomes in a national pediatric pulmonary hypertension service","volume":"206","author":"Constantine","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2025.12.013_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.111.026591","article-title":"Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.chest.2025.12.013_bib38","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/hrt.2009.182378","article-title":"Childhood idiopathic pulmonary arterial hypertension: a national cohort study","volume":"96","author":"Moledina","year":"2010","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.chest.2025.12.013_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ehjqcco\/qcad020","article-title":"Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry","volume":"10","author":"Ploegstra","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"10.1016\/j.chest.2025.12.013_bib40","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1164\/rccm.201406-1052OC","article-title":"Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry","volume":"190","author":"del Cerro Mar\u00edn","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.013_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.acvd.2009.12.001","article-title":"Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France","volume":"103","author":"Fraisse","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.chest.2025.12.013_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2019.04.062","article-title":"Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: an analysis of the TOPP registry","volume":"289","author":"Beghetti","year":"2019","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2025.12.013_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011306","article-title":"New strategies for the conduct of clinical trials in pediatric pulmonary arterial hypertension: outcome of a multistakeholder meeting with patients, academia, industry, and regulators, held at the European Medicines Agency on Monday, June 12, 2017","volume":"8","author":"Ollivier","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.chest.2025.12.013_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.681538","article-title":"Echocardiographic changes and long-term clinical outcomes in pediatric patients with pulmonary arterial hypertension treated with bosentan for 72 weeks: a post-hoc analysis from the FUTURE 3 study","volume":"9","author":"Beghetti","year":"2021","journal-title":"Front Pediatr"},{"issue":"9","key":"10.1016\/j.chest.2025.12.013_bib45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","article-title":"2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT","volume":"38","author":"Hansmann","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.chest.2025.12.013_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023118","article-title":"Prognostic value of transthoracic echocardiography in children with pulmonary arterial hypertension","volume":"12","author":"Lammers","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.chest.2025.12.013_bib47","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00246-017-1677-7","article-title":"Single-center experience using selexipag in a pediatric population","volume":"38","author":"Gallotti","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.chest.2025.12.013_bib48","article-title":"Case report: selexipag in pediatric pulmonary hypertension: initiation, transition, and titration","volume":"11","author":"Faircloth","year":"2023","journal-title":"Front Pediatr"}],"updated-by":[{"DOI":"10.1016\/j.chest.2026.06.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225059471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225059471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:33:44Z","timestamp":1787258024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369225059471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0012369225059471"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.013","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}